Basilea Pharmaceutica
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Basilea Pharmaceutica sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).
Basilea Pharmaceutica: 21 sponsored US clinical trials, 3 recruiting.
Basilea Pharmaceutica sponsors 21 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 14 completed. 5 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pharmacokinetics, with 2 trials.
Top-decile sponsor footprint
Basilea Pharmaceutica ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
14 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
21 total, page 1 of 1
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
NCT06925321
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
NCT06733675
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT05421858
Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ≤55 Years of Age
NCT06665555
Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age
NCT05856227
A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.
NCT05582187
Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function
NCT05488678
Food Effect on Ceftibuten/VNRX-7145 in Healthy Participants
NCT05527834
A Bioequivalence Study of APX001 High-load and Low-load Tablets
NCT05491733
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
NCT04604132
VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers
NCT04243863
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
NCT04240886
Derazantinib and Atezolizumab in Patients With Urothelial Cancer
NCT04045613
An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
NCT03604705
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
NCT03138733
Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
NCT03137173
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
NCT03250299
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
NCT03230318
Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics
NCT02527681
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
NCT01752920
Open Label Study of Ceftobiprole to Evaluate Pharmacokinetics in Adults Hospitalized in the ICU
NCT00770978
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 3 |
| Phase 3 | 5 |
What is open in the Basilea Pharmaceutica pipeline
3 recruiting of 21 indexed (14% open); 14 completed (67%).
Phase mix: 5 late (III/IV) vs 16 early (I/II) (early-phase heavy).
Top condition: Pharmacokinetics (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Basilea Pharmaceutica: open-pipeline peers nationwide
Peers matched on 21 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Basilea Pharmaceutica sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 21 trials (± recruiting share)
- AEterna Zentaris · 21 trials · 0% recruiting
- Amphastar Pharmaceuticals · 21 trials · 5% recruiting
- Apellis Pharmaceuticals · 21 trials · 10% recruiting
- Array Biopharma, now a wholly owned subsidiary of Pfizer · 21 trials · 0% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this Basilea Pharmaceutica page
21 registered trials is a research-attention snapshot, not an endorsement of Basilea Pharmaceutica or any single study.
- 3 of Basilea Pharmaceutica's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Pharmacokinetics is the condition Basilea Pharmaceutica studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pharmacokinetics trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Basilea Pharmaceutica pipeline card: 21 registered trials from official public datasets.Report a data error.